Home » Migenix Amends Protocol in Hepatitis C Study
Migenix Amends Protocol in Hepatitis C Study
Migenix will add a 600-mg celgosivir combination therapy arm to its Phase II study in treatment-naive hepatitis C patients.
The 12-week, randomized, active-controlled study initially enrolled 20 patients in two treatment arms: peginterferon alfa-2b plus ribavirin and the combination plus 400-mg celgosivir.
The approved protocol amendment allows for the addition of the 600-mg arm and the flexibility to increase the number of patients in the study to a maximum of 50, Migenix said.
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May